This website uses cookies. By browsing this website you agree to our use of cookies. That's fine Tell me more


Top Poster for Harry Potter

Harry says:
“I was delighted to win the prize for best poster at the School of Biological Sciences showcase day, on Friday 12th January.
“My poster presented data on placental gene expression in a rodent model for schizophrenia, as a part of my PhD project.
“The project forms part of a cross-faculty collaboration between the Divisions of Evolution & Genomic Sciences, Pharmacy & Optometry, and Developmental Biology & Medicine.”

See his poster.

Antonio Gonzalez wins the Dom Spina Prize

Antonio GonzalezBath placement student Antonio Gonzalez won the Veritas Pharma Inc. Dom Spina Prize, at the recent British Pharmacological Society meeting.

The award was for one of the best late-breaking abstracts, for his exercise project, conducted at b-neuro.

See his poster.

European College of Neuropsychopharmacology (ECNP) 2017

Jo presented a poster at the 30th ECNP congress 2-5th September 2017 in Paris, France, and a talk titled: Animal tests for Asociality and Avolition in the ECNP Targeted Network Meeting on Schizophrenia: beyond dopamine and psychosis on 6th September 2017.

See the poster.

British Association for Psychopharmacology (BAP) 2017

Jo is the president of the BAP, she presented a talk titled Markers of potential therapeutic efficacy for negative and cognitive symptoms in Symposium 9: Biomarkers of treatment response for schizophrenia and bipolar affective disorder: latest updates at their 43rd annual meeting in Harrogate, West Yorkshire 23-26th July 2017.

Ben Grayson, Joanna Oladipo, Antonio Gonzalez, Nazanin Doostdar, Sarah Lambert and Anneka Tomlinson presented their latest findings as posters at this meeting.

Nazanin and Antonio won poster prizes based on the high quality of their work and presentation and Joanna received the prestigious Hannah Steinberg bursary to attend the meeting based on the quality of her abstract.

See the posters (Ben, Antonio, Joanna & Nazanin), and the abstract for Jo’s talk.


Autifony has successfully completed a Phase I clinical trial with AUT00206. This will be followed by two important Phase 1b trials in collaboration with Bill Deakin at the University of Manchester and Oliver Howes at Kings College London.

See the Autifony press release.